Institute for Medical Immunology

Stanislas GORIELY

MD, PhD
stanislas.goriely@ulb.ac.be

F.R.S.-FNRS research associate


Degrees and relevant experience

His initial works focused on the ontogeny of innate immune cells and regulation of interleukin-12 family members during health and disease using molecular approaches and in vivo models.


Current research interests

  • Molecular mechanisms implicated in the control of inflammation

    The inflammatory response, elicited by pathogens or danger signals is critical for the initiation of immune responses. It involves molecules that will directly target infectious organisms and mediators such as chemokines and cytokines that will attract and educate other immune cells. This process has to be tightly controlled as acute inflammation can lead to tissue damage and chronic inflammatory states that are associated with a broad range of diseases, including autoimmunity, atherosclerosis and cancer. A few key cytokines that are expressed by activated macrophages and dendritic cells, including IL-12, IL-23 and IL-27 help dictate the type of adaptive immune response elicited in response to a pathogen. This project focuses on the control of cytokine production by innate cells. We study the implication of different mechanisms, including chromatin remodeling processes and mRNA destabilization. This project involves both in vitro molecular biology experiments and pre-clinical animal models.

  • Transcriptional control of memory CD8 T cell differentiation

    Cytotoxic T lymphocytes play an important role in our immune system. Indeed, upon infection, these lymphocytes rapidly proliferate and destroy infected or tumor cells. After this phase, a small fraction of these activated cells remains in the organism as «memory» cells, allowing the body to react more rapidly and efficiently in a subsequent infection. Memory cells are also at the basis of preventive vaccination. We further delineate the transcriptional mechanisms implicated in the acquisition of memory phenotype and functions. A better understanding of these mechanisms will have a direct impact on the development of novel vaccine approaches, for example against tuberculosis or AIDS virus.

  • Cellular and molecular mechanisms of action of vaccine adjuvants

    Among immunostimulatory molecules which have been considered as vaccine adjuvants over the last few decades, saponins and oil-in-water emulsions have been positively evaluated in clinical trials and used in several vaccines. These molecules activate the innate immune system efficiently but the pathways involved are poorly understood. In this project, we study these “non-conventional” molecular mechanisms using both in vitro and in vivo approaches.


Related publications

Martinet V, Tonon S, Torres D, Azouz A, Nguyen M, Kohler A, Flamand V, Mao C, Klein W, Leo O, Goriely S. Type I Interferons regulate Eomesodermin expression and the development of unconventional memory CD8+ T cells. Nat Comm. 2015. 6:7089.

Molle C., T. Zhang, L .Ysebrant, C. Gueydan, M. Andrianne, F. Sherer, G. Van Simaeys, P.J. Blackshear, O. Leo and S. Goriely. Tristetraprolin regulation of Interleukin-23 mRNA stability prevents a spontaneous inflammatory disease. 2013. J. Exp. Med. 210:1675-84.

Ysebrant de Lendonck L., S. Tonon, M. Nguyen, V. Martinet, C. Molle, L.M. Charbonnier, O. Leo and S. Goriely. Interferon Regulatory Factor 3 controls Interleukin-17 Expression in CD8 T lymphocytes. 2013. PNAS. 110:E3189-3197.

Levy O., S Goriely, and TR Kollmann. Immune response to vaccine adjuvants during the first year of life. 2013. Vaccine. 31:2500-2505.

Kollmann T.R., O. Levy, R.R. Montgomery, and S. Goriely. Innate immune function by Toll-like receptors: Distinct responses in newborns and the elderly. 2012. Immunity 37:771-83.

Goriely S., R. Cavoy and M. Goldman. Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders. 2009. Allergy. 64:702-709.

Goriely S., M. Neurath and M. Goldman. How microorganisms tip the balance between interleukin-12 family members. 2008. Nature Rev. Immunol. 8:81-86.